Coastline Trust Co Trims Position in Danaher Co. (NYSE:DHR)

Coastline Trust Co trimmed its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 27.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,344 shares of the conglomerate's stock after selling 3,117 shares during the period. Coastline Trust Co's holdings in Danaher were worth $2,320,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of DHR. Benjamin Edwards Inc. raised its holdings in shares of Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate's stock worth $538,000 after buying an additional 38 shares during the period. Wedge Capital Management L L P NC grew its position in Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate's stock valued at $342,000 after acquiring an additional 38 shares during the last quarter. Patrick M Sweeney & Associates Inc. increased its stake in Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate's stock worth $307,000 after purchasing an additional 40 shares during the period. Trust Co of Kansas lifted its position in shares of Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate's stock worth $255,000 after purchasing an additional 40 shares during the last quarter. Finally, Abacus Planning Group Inc. boosted its stake in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate's stock valued at $1,359,000 after purchasing an additional 40 shares during the period. Institutional investors own 79.05% of the company's stock.

Danaher Stock Down 3.7 %

NYSE DHR traded down $8.88 on Friday, hitting $230.50. The stock had a trading volume of 5,435,775 shares, compared to its average volume of 2,760,084. The business's fifty day moving average price is $262.20 and its 200 day moving average price is $260.38. The stock has a market cap of $166.49 billion, a price-to-earnings ratio of 43.99, a price-to-earnings-growth ratio of 4.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 52-week low of $206.30 and a 52-week high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the business earned $2.02 EPS. The firm's revenue for the quarter was up 3.1% on a year-over-year basis. Equities research analysts anticipate that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.47%. The ex-dividend date of this dividend was Friday, September 27th. Danaher's payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DHR. Wells Fargo & Company started coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $280.00 price target on the stock. The Goldman Sachs Group lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the company a "neutral" rating in a research note on Wednesday, July 24th. Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the company a "neutral" rating in a report on Wednesday, July 24th. Evercore ISI raised their price objective on Danaher from $275.00 to $278.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Finally, UBS Group lowered their target price on Danaher from $309.00 to $305.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, Danaher has a consensus rating of "Moderate Buy" and a consensus target price of $287.16.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the company's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company's stock, valued at $1,130,374.44. This represents a 18.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.